Advertisement

Surgical Management of the Axilla in Breast Cancer Patients with Negative Sentinel Lymph Node: A Method to Reduce False-Negative Rate

  • Qianqian Yuan
  • Gaosong WuEmail author
  • Shu-Yuan Xiao
  • Yukun He
  • Kun Wang
  • Dan Zhang
Original Scientific Report
  • 58 Downloads

Abstract

Background

False-negative rate (FNR) of sentinel lymph node dissection (SLND) has not been eliminated. The study was conducted to optimize the surgical resection of axilla in patients with negative sentinel lymph node (SLN) for the purpose of eradicating false-negative (FN) events of SLND.

Methods

A total of 312 clinically node-negative patients without neoadjuvant therapy underwent SLND with indocyanine green (ICG), methylene blue and the combination of ICG and methylene blue. Axillary dissection was performed subsequently regardless of the status of SLN. Lymph nodes were sent for pathological examination separately by serial resection every 0.5 cm away from marginally visualized SLNs.

Results

SLND was successfully conducted in 98.1% (306/312) of patients using methylene blue, ICG, and its combination. Further examination revealed 97 true-positive, 189 true-negative, and 13 FN results. The overall FNR was 11.8% (13/110). A horizontal line 1.5 cm away from the superior vSLN and a vertical line 1.5 cm away from the medial vSLN formed a zone of lower outer quadrant (LOQ) in axilla. Surgical resection of LOQ ‘en bloc’ showed a FNR of zero.

Conclusions

The surgical management of axilla may benefit negative SLN patients with potential nodal involvement, reducing the FNR of SLND to zero.

Trial registration number and agency

This study was registered with the Chinese Clinical Trial Registry (ChiCTR1800014247).

Notes

Acknowledgements

The authors thank the studied patients for their willingness to cooperate with our study.

Compliance with ethical standards

Conflict of interest

All the authors report no conflict of interest.

References

  1. 1.
    Veronesi U, Viale G, Paganelli G et al (2010) Sentinel lymph node biopsy in breast cancer. Ann Surg 251:595–600CrossRefGoogle Scholar
  2. 2.
    Giuliano AE, Chung AP (2010) Long-term follow-up confirms the oncologic safety of sentinel node biopsy without axillary dissection in node-negative breast cancer patients. Ann Surg 251:601–603CrossRefGoogle Scholar
  3. 3.
    Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553CrossRefGoogle Scholar
  4. 4.
    Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888CrossRefGoogle Scholar
  5. 5.
    Kim HJ, Son BH, Lim WS et al (2010) Impact of omission of axillary lymph node dissection after negative sentinel lymph node biopsy: 70-month follow-up. Ann Surg Oncol 17:2126–2131CrossRefGoogle Scholar
  6. 6.
    Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933CrossRefGoogle Scholar
  7. 7.
    Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599–609CrossRefGoogle Scholar
  8. 8.
    Lyman GH, Somerfield MR, Bosserman LD et al (2017) Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 35:561–564CrossRefGoogle Scholar
  9. 9.
    Zahoor S, Haji A, Battoo A et al (2017) Sentinel lymph node biopsy in breast cancer: a clinical review and update. J Breast Cancer 20:217CrossRefGoogle Scholar
  10. 10.
    Brown M, Assen FP, Leithner A et al (2018) Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 359:1408–1411CrossRefGoogle Scholar
  11. 11.
    Pereira ER, Kedrin D, Seano G et al (2018) Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 359:1403–1407CrossRefGoogle Scholar
  12. 12.
    James TA, Coffman AR, Chagpar AB et al (2016) Troubleshooting sentinel lymph node biopsy in breast cancer surgery. Ann Surg Oncol 23:3459–3466CrossRefGoogle Scholar
  13. 13.
    Boughey JC, Suman VJ, Mittendorf EA et al (2015) Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 261:547–552CrossRefGoogle Scholar
  14. 14.
    Boughey JC, Ballman KV, Le-Petross HT et al (2016) Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy. Ann Surg 263:802–807CrossRefGoogle Scholar
  15. 15.
    Martin RCG, Chagpar A, Scoggins CR et al (2005) Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg 241:1005–1015CrossRefGoogle Scholar
  16. 16.
    Sugie T, Kassim KA, Takeuchi M et al (2010) A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer. Cancers 2:713–720CrossRefGoogle Scholar
  17. 17.
    Ersoy YE, Kadioglu H (2018) Review of novel sentinel lymph node biopsy techniques in breast cancer patients treated with neoadjuvant chemotherapy. Clin Breast Cancer 18:e555–e559CrossRefGoogle Scholar
  18. 18.
    Gill G (2009) Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 16:266–275CrossRefGoogle Scholar
  19. 19.
    Wetzig N, Gill PG, Espinoza D et al (2017) Sentinel-lymph-node-based management or routine axillary clearance? five-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial: assessment and incidence of true lymphedema. Ann Surg Oncol 24:1064–1070CrossRefGoogle Scholar
  20. 20.
    Takeuchi M, Sugie T, Abdelazeem K et al (2012) Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer. Breast J 18:535–541CrossRefGoogle Scholar
  21. 21.
    Thompson M, Korourian S, Henry-Tillman R et al (2007) Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 14:1890–1895CrossRefGoogle Scholar
  22. 22.
    Nos C, Lesieur B, Clough KB et al (2007) Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol 14:2490–2496CrossRefGoogle Scholar
  23. 23.
    Imoto S (2004) Prognosis of breast cancer patients treated with sentinel node biopsy in Japan. Jpn J Clin Oncol 34:452–456CrossRefGoogle Scholar
  24. 24.
    Sugie T, Kinoshita T, Masuda N et al (2016) Evaluation of the clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol 23:44–50CrossRefGoogle Scholar
  25. 25.
    van der Vorst JR, Schaafsma BE, Verbeek FPR et al (2012) Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99 m technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol 19:4104–4111CrossRefGoogle Scholar
  26. 26.
    Sparano JA (2018) Neoadjuvant systemic therapy for breast cancer: searching for more effectively curative therapies. Jama Oncol 4:293–295CrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2018

Authors and Affiliations

  • Qianqian Yuan
    • 1
  • Gaosong Wu
    • 1
    Email author
  • Shu-Yuan Xiao
    • 2
    • 3
  • Yukun He
    • 1
  • Kun Wang
    • 4
  • Dan Zhang
    • 4
  1. 1.Department of Thyroid and Breast SurgeryZhongnan Hospital of Wuhan UniversityWuhanPeople’s Republic of China
  2. 2.Wuhan University Center for Pathology and Molecular DiagnosticsWuhanPeople’s Republic of China
  3. 3.Department of PathologyUniversity of ChicagoChicagoUSA
  4. 4.Department of Thyroid and Breast SurgeryTongji Hospital of Tongji Medical College of Huazhong University of Science and TechnologyWuhanPeople’s Republic of China

Personalised recommendations